Topic:

Supply Chain and Manufacturing

Latest Headlines

Latest Headlines

UPDATED: India's Wockhardt recalls millions of packages of drugs in sweeping recall

When India's Wockhardt acknowledged recently it was pulling all of the drugs still on the market that it had shipped before the FDA banned two of its plants, it didn't say what those numbers might add up to. Try hundreds of millons of tablets and capsules.

Eisai turns North Carolina facility over to Biogen as it continues its cost-cutting

Eisai has been whittling down its U.S. workforce as part of broader cost-cutting moves in the face of a tough patent cliff go. Now the Japanese drugmaker will trim another 135 people from its payroll with the sale of a manufacturing facility in North Carolina to drug development partner Biogen.

Pfizer closing India plant, laying off workers

Pfizer intends a close one of its plants in India, a facility that has sat mostly idle for two years. But it is not as if Pfizer will be short on manufacturing capacity in the country. As soon as it completes its $15 billion deal to buy Hospira, it will get that company's massive manufacturing network there, including a brand-spanking-new plant in Vizag.

J&J set to reopen McNeil plant amid consumer biz overhaul

Johnson & Johnson is moving closer to resolving its consumer healthcare woes, preparing to reopen a Philadelphia-area factory that was once at the center of the drama.

Biogen to build $1B plant, add 400 jobs in Switzerland

Biogen has looked at its pipeline of promising drug candidates for things like Alzheimer's disease and multiple sclerosis, measured that against its manufacturing network and decided it is going to need more capacity. The company announced on Tuesday that it will start with a $1 billion plant in Switzerland, where it expects to add 400 jobs.

Pharma to EU officials: We need 'contingency' supply plans in case of 'Grexit'

Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, the European Federation of Pharmaceutical Industries and Associations warned European Commission officials, with suddenly cheap meds in Greece diverted for sale at higher prices in neighboring EU countries.

Mylan expands cancer drug recall on particle contamination worries

Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began in April because they may contain particulate.

AstraZeneca takes its emerging markets push to Algeria with $125M expansion

AstraZeneca CEO Pascal Soriot has made emerging markets part of his 5-point campaign to rebuild the drugmaker's financial health. And now he is taking that piece of his campaign to North Africa, where AstraZeneca is part of a joint venture to build a $125 million plant.

Groundbreaking held for the new $1.2B NABF animal health facility in Kansas

A groundbreaking ceremony was held Wednesday for the $1.2 billion National Bio and Agro-Defense Facility (NABF) currently under construction in Kansas.

AstraZeneca, betting on biologics, will build a $285M facility in Sweden

AstraZeneca CEO Pascal Soriot is counting on the company's cancer drug pipeline to help it climb out of the revenue hole it has fallen into, and he figures his company needs more manufacturing capacity for the coming launches.